✦ LIBER ✦

Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials

✍ Scribed by Petrelli, Fausto; Barni, Sandro

Book ID: 121577973
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 244 KB
Volume: 31
Category: Article
ISSN: 1357-0560
DOI: 10.1007/s12032-013-0776-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Surrogate End Points and Postprogression

Surrogate End Points and Postprogression Survival in Renal Cell Carcinoma: An Analysis of First-Line Trials With Targeted Therapies

✍ Petrelli, Fausto; Barni, Sandro 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 625 KB

Phase III trial of liposomal doxorubicin

Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer

✍ Chan, S. 📂 Article 📅 2004 🏛 Oxford University Press 🌐 English ⚖ 91 KB

Myotax: A phase II trial of docetaxel pl

Myotax: A phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines

✍ E. Curtit; P. Nouyrigat; N. Dohollou; E. Levy; A. Lortholary; J. Gligorov; T. Fa 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 356 KB

Randomized Phase III Placebo-Controlled

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

✍ Wolff, A. C.; Lazar, A. A.; Bondarenko, I.; Garin, A. M.; Brincat, S.; Chow, L.; 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 194 KB

1423 POSTER Polymorphism Analysis in the

1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)

✍ D.W. Miles; S.L. De Haas; G. Romieu; A. Chan; L. Dirix; J. Cortes; P.R. Delmar; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

2098 ORAL BCIRG 007: First overall survi

2098 ORAL BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)

✍ T. Pienkowski; M. Pegram; J. Forbes; V. Valero; W. Eiermann; G. Von Minckwitz; M 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 77 KB